医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

CDISC is Proud to Announce a Research Collaboration to Incorporate FDA Business Rules into CDISC’s Open Rules Engine (CORE)

2024年01月17日 AM02:32
このエントリーをはてなブックマークに追加


 

AUSTIN, Texas

CDISC is proud to announce a research collaboration with the U.S. Food and Drug Administration’s Office of Translational Sciences in the Center for Drug Evaluation and Research and Office of Regulatory Operations in the Center for Biologics Evaluation and Research to incorporate FDA Business Rules into CDISC’s Open Rules Engine (CORE).

CDISC’s CORE project provides an open-source version of the CDISC Conformance Rules in a machine-executable format. These rules, published and managed by CDISC, create a single source for conformance rules and allow external vendors and sponsor companies to implement and extend these rules within their tools. FDA Business Rules are currently written in a plain text, non-machine executable format and describe the business requirements for regulatory review to help ensure that clinical trial study data is compliant and useful and supports meaningful review and analysis.

The goal of this effort, which began on November 3rd, 2023 and has term of three (3) years, is to collaborate on providing input on machine-executable formats of the FDA Business Rules and on the development and ongoing governance of this set of executable rules within CORE that can be used by sponsors of medical product applications.

“CDISC is grateful for the opportunity to partner with CDER and CBER to establish a single source for machine-executable Conformance Rules and drive the implementation by the industry,” said Peter Van Reusel, Chief Standards Officer at CDISC.

The benefits of creating a single comprehensive and credible source of validation rules include increasing access, transparency, and visibility of validation rules used to ensure the quality and usability of study data in FDA. This will enable sponsors to submit high quality study data that will be ready for regulatory review saving time and effort for all parties involved.

“Our research collaboration with CDISC is an important step to ensure that study data validation rules are understandable and accessible to all,” said Lilliam Rosario, Ph.D., Director, Office of Computational Science, Office of Translational Sciences, CDER.

About CDISC

Clinical Data Interchange Standards Consortium (CDISC) is a global non-profit organization that develops and advances data standards of the highest quality to transform incompatible formats, inconsistent methodologies, and diverse perspectives into a robust framework for generating accessible clinical research data. Driven by the belief that the true measure of data is its impact, CDISC convenes a global community of research experts representing a range of experiences and backgrounds to harness the collective power to drive more meaningful clinical research.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240116117632/en/

CONTACT

Melissa Kirwin

mkirwin@cdisc.org

同じカテゴリーの記事 

  • FPT Software Renews HITRUST r2 Certification, Upholding The Highest Standards Of Security And Compliance
  • Rapid Medical™使用全球首台机器人血栓切除设备成功完成缺血性中风手术
  • ラピッド・メディカル™が世界初のロボット血栓除去装置で虚血性脳卒中手技を成功裏に完了
  • AriBio获得国家药品监督管理局对一项治疗早期阿尔茨海默病的3期临床试验POLARIS-AD的IND批准
  • AriBio Receives IND Approval from China’s NMPA for POLARIS-AD, a Phase 3 Trial for the Treatment of Early Alzheimer’s Disease